Your guide to pharma Q1 numbers; Unpacking top 15 R&D giants; Secret PhIII failures; 'Weirdo science' and metascience; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
It’s not an easy time to be in biotech, but as the saying goes, the industry has never been for the faint-hearted. We have all the news covered — and then some — in this week’s edition, alongside a full slate of stories from EndpointsPharma to all through earnings week. Have a restful weekend.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,100+ biopharma pros reading Endpoints daily — and it's free.